Why Biohaven Stock Plummeted by More Than 15% Today

In Friday news Biohaven (NYSE: BHVN) She withdrew her request to obtain the largest investigative drug from an important organizer, investors were traded strongly outside the shares. The biotechnology of the clinical stage was one of the largest storage operations in its industry, as it came out on Friday with the share price of more than 15 %. This was during a session that was mainly optimistic. the S & P 500 A closed index 0.6 % higher.

This news did not come from Biohaven itself, but from the European Pharmaceutical Agency (EMA, the European Union’s drug regulator of 27 countries). In a statement, EMA revealed that a company affiliated with the company withdrew its request to obtain marketing permit Toriluzole, described as a name Dazluma. The agency added that this step on March 24.

Where are you investing $ 1,000 now? Our analyst team has just revealed what they think 10 best stocks To buy now. He continues.

Biohaven originally applied for this license to the Daziloma at the end of 2023. The surveys targets a rare genetic painful for neurons called Spinocerebelalar Ataxia Type 3.

According to EMA, she evaluated Biohaven information about Dazluma and prepared a series of questions for the company. The agency noted that it had many issues that relieved approval.

Although Biohaven has not yet made an official statement about her withdrawal from Dazluma, she sent a message to EMA stating its reasons. The agency wrote that in the letter, Biohaven said, “It plans to create additional data for new support Active Case “for drugs.

In addition, according to EMA, the company intends to “submit a new application once you create this data.”

Regardless, any retreat from organizational application is a major blow to investor morale. The European Union is huge and sprawling, and thus has one of the largest patients in any judicial state all over the world.

Before purchasing shares in Biohaven, think about this:

the Motley Adviser is a lie The analyst’s team has just identified what they think 10 best stocks For investors to buy now … BIOHAVEN was not one of them. The ten shares that made the pieces can produce monster revenues in the coming years.

Look at when Netflix This list was submitted on December 17, 2004 … if you invest $ 1,000 at the time of our recommendation, You will have 591,533 dollars! Or when Nafidia This list was presented on April 15, 2005 … if you invest $ 1,000 at the time of our recommendation, You will have 652,319 dollars!

Now, it is worth noting Stock consultantAverage overall return 859 %-Suspestness in the market compared to 158 % For S&P 500. Don’t miss the latest 10 best list, available when joining Stock consultant.

See the ten stocks »